Improved <i>in vitro</i> fertilization success and pregnancy outcome with autologous platelet-rich plasma treatment in unexplained infertility patients that had repeated implantation failure history

Çoksüer, Hakan; Akdemir, Yeşim; Barut, Mert Ulaş

doi:10.1080/09513590.2019.1597344

Cited by 50 publications

(39 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The resulting average endometrial thicknesses of 10 and 8 mm in the PRP and estradiol groups, respectively, enabled FET in all cases. PRP therapy afforded higher rates of clinical pregnancy and live births (14% vs 6%), as well as a lower occurrence of miscarriages (3% vs 6%), when compared to estradiol therapy (Coksuer, Akdemir & Barut, 2019). Additionally, in a study by , intrauterine administration of autologous PRP improved implantation and pregnancy outcomes for patients with refractory thin endometrium-associated infertility, indicating profound functional consistency of the effects of PRP.…”

Section: Introductionmentioning

confidence: 90%

See 1 more Smart Citation

Effects of platelet-rich plasma on mesenchymal stem cells isolated from rat uterus

Vishnyakova

Artemova

Elchaninov

et al. 2020

PeerJ

View full text Add to dashboard Cite

Background Platelet-rich plasma (PRP), which represents a valuable source of growth factors, is increasingly being applied in regenerative medicine. Recent findings suggest the feasibility of using PRP in the treatment of infertility secondary to refractory thin endometrium. Mesenchymal stem/stromal cells (MSCs) of the endometrium are an essential cellular component responsible for extracellular matrix remodeling, angiogenesis, cell-to-cell communication, and postmenstrual tissue repair. Using a rat model, we examine the effects of autologous PRP on MSCs isolated from the uterus and compare them with the effects of autologous ordinary plasma (OP) and complete growth medium. Methods MSCs were isolated from uterine tissues via enzymatic disaggregation. Flow cytometry immunophenotyping of the primary cell cultures was complemented by immunocytochemistry for Ki-67 and vimentin. The ability of MSCs to differentiate in osteo-, chondro-, and adipogenic directions was assessed using differentiation-inducing media. The levels of autophagy and apoptosis markers, as well as the levels of matrix metalloproteinase 9 (MMP9) and estrogen receptor α, were assessed by western blotting. Results After 24 h incubation, the proliferation index of the PRP-treated MSC cultures was significantly higher than that of the MSC cultures treated with complete growth medium. PRP treatment elevated production of LC3B protein, an autophagy marker, while OP treatment upregulated the expression of stress-induced protein p53 and extracellular enzyme MMP9. The results indicate practical relevance and validity for PRP use in the treatment of infertility.

show abstract

Section: Introductionmentioning

confidence: 90%

“…As a result, 5 (50%) of the patients successfully entered pregnancy (Zadehmodarres et al, 2017). Coksuer, Akdemir & Barut (2019), evaluated PRP treatment of thin endometrium as an alternative to estradiol therapy in patients with a history of three or more failed IVF cycles.…”

Section: Introductionmentioning

confidence: 99%

Effects of platelet-rich plasma on mesenchymal stem cells isolated from rat uterus

Vishnyakova

Artemova

Elchaninov

et al. 2020

PeerJ

View full text Add to dashboard Cite

show abstract

“…The regenerative potential of platelet-rich products has also been tested in tympanic perforation (51,52), skin lesions (53) -such as skin ulcers of multifactorial etiology: diabetic foot (54-56), pressure ulcers (57,58), venous ulcers (59) and even leprosy ulcers (60)-, vitiligo (61) and androgenetic alopecia (62). In the area of gynecology there are reports of the use of PRP to aid wound healing and recovery in caesarean delivery, vulvovaginal atrophy, benign cervical ectopy and it has also been applied in reproductive medicine and erectile dysfunction (63)(64)(65)(66)(67)(68)(69).…”

Section: Clinical Uses Of Platelet-derived Bio-products and Concerns:mentioning

confidence: 99%

Platelet-derived bio-products: Classification update, applications, concerns and new perspectives

Acebes-Huerta

Arias-Fernández

Bernardo

et al. 2020

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Platelet derived bio-products in the form of platelet rich plasma, plasma rich in growth factors, or plasma-free platelet releasates, are being studied worldwide with the aim of proving their efficacy in tissue regeneration within many different clinical areas, such as traumatology, maxillofacial surgery, ophthalmology, dermatology and otorhinolaryngology, amongst others. The current lack of consensus in the preparation method and application form, or in the quality assessment of each bio-product, precludes adequate interpretation of the relevance of reported clinical outcomes, and while many clinicians are very positive about them, as many are sceptic. Relevant aspects of these products are considered to propose a classification nomenclature, which would aid at the comprehensive comparison of clinical outcomes of bio-products of the same characteristics. Finally, the uses of platelet-derived bio-products in in vitro culture (for cell therapy purposes) as a substitute of animal-origin sera, and other future perspectives of applications of platelet-derived bio-products are discussed.

show abstract

“…Platelet-rich plasma Platelet-rich plasma (PRP) is an experimental intervention, initially geared at addressing poor proliferation and suboptimal endometrial thickness by promoting tissue regeneration. Several small, observational studies have demonstrated a positive impact of intrauterine infusion of PRP on endometrial thickness and pregnancy rates 74,75 . The largest available RCT was performed by Nazari et al in 138 RIF patients and supported a possible benefit 76 .…”

Section: Endometrial Injury or "Scratch"mentioning

confidence: 99%

Diagnostic and therapeutic options in recurrent implantation failure

Moustafa

Young

2020

F1000Res

View full text Add to dashboard Cite

Recurrent implantation failure (RIF) is an uncommon, imprecisely defined clinical disorder characterized by failure to achieve pregnancy after repeated embryo transfers. The diverse etiologies and incomplete understanding of RIF provide significant diagnostic and therapeutic challenges to patients and providers. Careful clinical evaluation prior to assisted reproduction can uncover many treatable causes, including thyroid dysfunction, submucosal myomas, and tobacco use. The more-subtle causes often require a more-targeted assessment. Undetected, small polyps or small areas of intrauterine synechiae are relatively common and easily treated contributors to RIF. Molecular and cellular abnormalities pose a greater therapeutic challenge. Putative causes of RIF, including progesterone resistance, shifted window of receptivity, decreased integrin expression, and immunologic disturbances, should be considered in the evaluation of a patient with otherwise unexplained RIF. It may also be true that a more complex and standardized definition of RIF would be helpful in these cases. In this paper, we review the diagnostic and therapeutic approaches to RIF, with emphasis on disorders of endometrial receptivity.

show abstract

Improved in vitro fertilization success and pregnancy outcome with autologous platelet-rich plasma treatment in unexplained infertility patients that had repeated implantation failure history

Cited by 50 publications

References 19 publications

Effects of platelet-rich plasma on mesenchymal stem cells isolated from rat uterus

Effects of platelet-rich plasma on mesenchymal stem cells isolated from rat uterus

Platelet-derived bio-products: Classification update, applications, concerns and new perspectives

Diagnostic and therapeutic options in recurrent implantation failure

Contact Info

Product

Resources

About